BIOMERICA INC
BMRANasdaqHealthcare · In Vitro & In Vivo Diagnostic Substances · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $5.3M | $5.4M | $5.3M | $18.9M | $7.2M | $6.7M |
| Operating income | −$5.1M | −$6.4M | −$7.2M | −$4.5M | −$7.5M | −$2.4M |
| Net income | −$5.0M | −$6.0M | −$7.1M | −$4.5M | −$7.4M | −$2.3M |
| Total assets | $5.9M | $9.3M | $14.5M | $11.4M | $11.8M | $17.3M |
| Total liabilities | $1.8M | $2.7M | $2.7M | $3.0M | $2.6M | $3.0M |
| Equity | $4.1M | $6.6M | $11.7M | $8.3M | $9.2M | $14.2M |
| EPS (diluted) | $-2.16 | $-2.84 | $-0.50 | $-0.36 | $-0.62 | $-0.23 |
| Shares out. | 2.8M | 16.8M | 16.8M | 13.4M | 12.5M | 11.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −96.7%
- Net margin
- −93.6%
- Return on equity
- −121.1%
- Return on assets
- −83.7%
- Return on capital (ROCE)
- −122.2%
- Liabilities / assets
- 31.0%
- Debt / equity
- 0.45×
- Book value / share
- $1.46
- Revenue growth (YoY)
- −1.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -29.16distress
- Accruals / assets
- −19.0%clean
- Beneish M-Score
- -3.47normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Aug 30, 2011
- NT 10-Qmissed a reporting deadline ↗Jan 15, 2010
- NT 10-Qmissed a reporting deadline ↗Oct 16, 2009
- NT 10-Qmissed a reporting deadline ↗Jan 17, 2006
- NT 10-Qmissed a reporting deadline ↗Oct 17, 2005
- NT 10-Kmissed a reporting deadline ↗Aug 29, 2005
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 91,606 | 4.2 | +44.5% |
| Apr 30, 2026 | 63,380 | 4.2 | +3.8% |
| Apr 15, 2026 | 61,056 | 2.0 | -17.0% |
| Mar 31, 2026 | 73,534 | 2.8 | +63.0% |
| Mar 13, 2026 | 45,117 | 2.3 | -26.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteDec 16, 2025
- Director / officer change · Regulation FD disclosureOct 8, 2025
- Director / officer change · Regulation FD disclosureJun 6, 2025
- Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureApr 16, 2025
- Shareholder voteDec 17, 2024
- Delisting / listing-standard noticeNov 6, 2024
- Director / officer changeJun 28, 2024
- Entered a material agreement · Delisting / listing-standard noticeMay 10, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.